TIDMONT
Oxford Nanopore Technologies plc
31 October 2023
Oxford Nanopore Technologies plc
Apple showcases Oxford Nanopore in M3 silicon chip launch
31 October 2023
Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"),
the company delivering a new generation of nanopore-based molecular
sensing technology, was showcased in Apple Inc.'s global product
launch on Monday. Apple positioned Oxford Nanopore's DNA/RNA
sequencing technology as a companion platform that can run on Apple
devices equipped with its new M3 silicon chips, supporting broad
access to biological insights in scientific research, health,
agriculture and industry.
In a blog post , Apple said that its latest M3 silicon chip is
now even faster and more powerful to support improved nanopore
sequencing, seamlessly integrating with Oxford Nanopore's onboard
MinKNOW software to run and analyse DNA/RNA reads from the
small-format Oxford Nanopore sequencing devices, the MinION and
PromethION 2 Solo. Both products rely on external computing power
to process the electrical signals from the nanopore platform.
The upgrade means that anyone with an M3-enabled Apple product,
including the Macbook Pro(TM) and iMac(TM), will be able to access
the same high-definition sequencing data with the MinION or P2 Solo
alongside their Apple device. This further enhances the experience
over M1 or M2 users and supports future improvements in nanopore
sequencing data outputs. The sequencing data is then turned into
usable insight through a range of software applications. Oxford
Nanopore's higher-output devices that include onboard computing,
including the GridION and PromethION 24 and 48, will continue to be
powered by NVIDIA's A-series towers.
The new M3 chips' compute capacity can process thousands of
inputs at once and in real time - similar to processing 6,000
conversations with Siri simultaneously. Pairing the M3 chip-enabled
products with Oxford Nanopore's affordable and accessible MinION
and P2 Solo sequencing devices has the potential to enable more
global communities to access faster, richer biological data,
powered by the latest machine learning technology.
Gordon Sanghera, CEO of Oxford Nanopore, commented:
"We are incredibly proud to be showcased by Apple as a
complementary technology that can seamlessly integrate with Apple's
new silicon chips, which is even faster and more powerful to
support real-time nanopore DNA/RNA sequencing. Powered by Apple's
M3 silicon chips, we are one step closer to achieving our vision of
enabling the analysis of anything by anyone, anywhere by making it
possible for more scientists around the world to access real-time,
data rich DNA/RNA insights with only a MinION or P2 Solo and an
iMac or Macbook Pro."
Read more from Gordon here .
[ENDS]
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology that is currently used for
real-time, high-performance, accessible, and scalable analysis of
DNA and RNA. The technology is used in more than 120 countries, to
understand the biology of humans, plants, animals, bacteria,
viruses and environments as well as to understand diseases such as
cancer. Oxford Nanopore's technology also has the potential to
provide broad, high impact, rapid insights in a number of areas
including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
Forward-looking statements
This announcement contains certain forward-looking statements.
For example, statements regarding expected revenue growth and
profit margins are forward-looking statements. Phrases such as
"aim", "plan", "expect", "intend", "anticipate", "believe",
"estimate", "target", and similar expressions of a future or
forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future
business and financial performance and financial condition, and by
definition address matters that are, to different degrees,
uncertain. Our results could be affected by macroeconomic
conditions, the COVID-19 pandemic, delays in our receipt of
components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFIFFRITLLVIV
(END) Dow Jones Newswires
October 31, 2023 03:00 ET (07:00 GMT)
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Apr 2023 to Apr 2024
